IL253795B - Methods for treating cancer using activated t cells - Google Patents

Methods for treating cancer using activated t cells

Info

Publication number
IL253795B
IL253795B IL253795A IL25379517A IL253795B IL 253795 B IL253795 B IL 253795B IL 253795 A IL253795 A IL 253795A IL 25379517 A IL25379517 A IL 25379517A IL 253795 B IL253795 B IL 253795B
Authority
IL
Israel
Prior art keywords
activated
cells
methods
cancer treatment
cancer
Prior art date
Application number
IL253795A
Other languages
English (en)
Hebrew (he)
Other versions
IL253795A0 (en
Original Assignee
Syz Cell Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syz Cell Therapy Co filed Critical Syz Cell Therapy Co
Publication of IL253795A0 publication Critical patent/IL253795A0/en
Publication of IL253795B publication Critical patent/IL253795B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL253795A 2015-03-13 2017-08-02 Methods for treating cancer using activated t cells IL253795B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/074227 WO2016145578A1 (en) 2015-03-13 2015-03-13 Methods of cancer treatment using activated t cells
PCT/CN2016/076165 WO2016146035A1 (en) 2015-03-13 2016-03-11 Methods of cancer treatment using activated t cells

Publications (2)

Publication Number Publication Date
IL253795A0 IL253795A0 (en) 2017-09-28
IL253795B true IL253795B (en) 2021-06-30

Family

ID=56918222

Family Applications (2)

Application Number Title Priority Date Filing Date
IL253795A IL253795B (en) 2015-03-13 2017-08-02 Methods for treating cancer using activated t cells
IL283733A IL283733A (en) 2015-03-13 2021-06-06 Methods of cancer treatment using activated t cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL283733A IL283733A (en) 2015-03-13 2021-06-06 Methods of cancer treatment using activated t cells

Country Status (9)

Country Link
US (4) US10967054B2 (https=)
EP (2) EP4219690A3 (https=)
JP (3) JP6856534B2 (https=)
KR (2) KR20240069809A (https=)
CN (3) CN107735492B (https=)
CA (1) CA2975602A1 (https=)
IL (2) IL253795B (https=)
RU (1) RU2729362C2 (https=)
WO (2) WO2016145578A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
BR112019006652A2 (pt) * 2016-10-13 2019-07-02 Juno Therapeutics Inc métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
JP7080458B2 (ja) * 2016-10-14 2022-06-06 国立大学法人京都大学 Ｐｄ－１経路阻害薬の薬剤感受性を判定する方法
WO2018071576A1 (en) * 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
CN109952308B (zh) * 2016-11-29 2022-09-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
WO2018102761A1 (en) * 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
UY37594A (es) * 2017-02-07 2018-08-31 Univ Saitama Medical Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer
US11229668B2 (en) 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
JP2020506943A (ja) * 2017-02-07 2020-03-05 メモリアル スローン ケタリング キャンサー センター 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
JP7763588B2 (ja) * 2017-09-05 2025-11-04 グリットストーン バイオ インコーポレイテッド Ｔ細胞療法用の新生抗原の特定法
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
CN111801415A (zh) * 2017-11-06 2020-10-20 路德维格癌症研究院 扩增淋巴细胞的方法
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
US10363008B2 (en) * 2017-11-27 2019-07-30 Canon Medical Systems Usa, Inc. Computed tomography perfusion (CTP) method and apparatus using blood flow for discriminating types of cancer
US20200368336A1 (en) * 2017-12-01 2020-11-26 Shanghai Jenomed Biotech Co., Ltd. Method for preparing personalized cancer vaccine
CN111670040A (zh) * 2018-01-08 2020-09-15 密歇根大学董事会 Aldh1抗原冲击树突状细胞
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells
CN112512538A (zh) * 2018-05-18 2021-03-16 国家儿童医疗中心 改进的靶向t细胞疗法
JP7466519B2 (ja) 2018-07-23 2024-04-12 ガーダント ヘルス， インコーポレイテッド 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム
CA3106562A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
WO2020022899A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US20210172961A1 (en) * 2018-07-27 2021-06-10 Board Of Regents, The University Of Texas System Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer
CN109294997B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种lrfft1细胞
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
CN109295106B (zh) * 2018-09-30 2020-07-24 北京鼎成肽源生物技术有限公司 一种hafft1细胞
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019373241A1 (en) * 2018-10-29 2021-06-10 Genocea Biosciences, Inc. Treatment methods
WO2020106982A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods of overcoming resistance to immune checkpoint inhibitors
US20220296642A1 (en) * 2018-12-04 2022-09-22 Nantomics, Llc Methods of Making Therapeutic T Lymphocytes
EP3908293A4 (en) * 2019-01-07 2023-01-11 Children's National Medical Center EX VIVO ACTIVATED T LYMPHOCYTE COMPOSITIONS AND METHODS OF USE THEREOF
WO2020160285A1 (en) * 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
CA3131777A1 (en) * 2019-03-01 2020-09-10 Flow Pharma Inc. Design, manufacture, and use of personalized cancer vaccines
CN111751545A (zh) * 2019-03-28 2020-10-09 中国科学院上海药物研究所 一种筛选pd-l1/pd-1检测点抑制剂的方法
WO2020227279A1 (en) * 2019-05-06 2020-11-12 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
KR20220026575A (ko) * 2019-06-25 2022-03-04 시티 오브 호프 Pdl1 양성 nk 세포 암 치료
CN114599378A (zh) * 2019-10-31 2022-06-07 公立大学法人福岛县立医科大学 用于肿瘤的治疗和/或预防的组合物
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.
CN111337681A (zh) * 2020-03-20 2020-06-26 上海东方肝胆外科医院 评估肝细胞癌预后的标志物、试剂盒及方法
WO2021219990A1 (en) * 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
CN116018158A (zh) * 2020-04-30 2023-04-25 转化基因组学研究所 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
CN111575232A (zh) * 2020-05-15 2020-08-25 暨南大学 JQ1在抑制T淋巴细胞PD-1和/或Tim-3表达中的应用
CN111647563A (zh) * 2020-08-06 2020-09-11 北京翊博普惠生物科技发展有限公司 靶向Survivin全抗原的DC细胞、CTL细胞及其制备方法和应用
WO2022059780A1 (ja) * 2020-09-18 2022-03-24 サイアス株式会社 ｉＰＳ細胞を介する再生Ｔ細胞の製造方法
CN112501308B (zh) * 2020-11-30 2025-10-10 中国水产科学研究院珠江水产研究所 一组鳖科动物线粒体全基因组扩增通用引物
CN114045272B (zh) * 2021-03-24 2024-12-06 深圳市新靶向生物科技有限公司 一种与乳腺癌驱动基因突变相关的抗原肽组合及其应用
TW202317754A (zh) * 2021-06-30 2023-05-01 日商諾瓦瑟拉姆股份有限公司 製備含有血中循環腫瘤細胞之樣品之方法
EP4422668A1 (en) * 2021-10-25 2024-09-04 Ellennbe GmbH Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases
KR102732911B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732909B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
CN115998851A (zh) * 2022-12-28 2023-04-25 四川康德赛医疗科技有限公司 一种个体化mRNA组合物、载体、mRNA疫苗及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5388946A (en) 1988-01-20 1995-02-14 Grau Gmbh & Co. Systems and methods for the automated archiving and retrieval of computer data storage cassettes
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US20040110283A1 (en) 1997-02-27 2004-06-10 University Of Pittsburgh Of The Commonwealth System Of Higher Education Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
WO2000057705A1 (en) 1999-03-31 2000-10-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
DK1224264T3 (da) 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
JP2004501631A (ja) 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
CA2448599A1 (en) 2001-04-27 2002-11-07 Invitrogen Corporation Maturation of antigen-presenting cells using activated t cells
KR20080109717A (ko) 2005-12-08 2008-12-17 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한조성물 및 방법
EP3375868A1 (en) 2007-11-08 2018-09-19 Dana Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
HUE029914T2 (en) 2008-04-03 2017-04-28 Cb Biotechnologies Inc Amplicon-saving multiplex polymerase chain reaction for amplification of multiple targets
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
JP5816627B2 (ja) 2009-10-27 2015-11-18 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
JP6293674B2 (ja) * 2012-01-13 2018-03-14 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 構造化ポリマー装置におけるｔｌｒアゴニストの制御送達
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
WO2016154628A1 (en) 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
US20180171294A1 (en) 2015-03-26 2018-06-21 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
CN104946588A (zh) 2015-07-07 2015-09-30 英普乐孚生物技术(上海)有限公司 一种抗原特异性t淋巴细胞的分离和高效扩增培养方法
CN106645677B (zh) 2016-11-15 2019-08-09 恒瑞源正（上海）生物科技有限公司 体外检测肿瘤新生抗原特异性t细胞的方法、试剂盒以及肿瘤疫苗
HUE058957T2 (hu) 2016-12-08 2022-10-28 Immatics Biotechnologies Gmbh Új T-sejt receptorok és velük végzett immunterápia
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors

Also Published As

Publication number Publication date
EP3268465A4 (en) 2018-08-08
KR20240069809A (ko) 2024-05-20
CN107735492B (zh) 2022-04-05
RU2017134270A3 (https=) 2020-01-10
IL283733A (en) 2021-07-29
EP3268465B1 (en) 2023-03-29
US11229689B2 (en) 2022-01-25
US20210268083A1 (en) 2021-09-02
KR102698909B1 (ko) 2024-08-26
KR20170122270A (ko) 2017-11-03
IL253795A0 (en) 2017-09-28
US11219675B2 (en) 2022-01-11
JP2021059611A (ja) 2021-04-15
EP4219690A2 (en) 2023-08-02
EP4219690A3 (en) 2023-08-30
US20180078624A1 (en) 2018-03-22
CN107735492A (zh) 2018-02-23
CN115501331A (zh) 2022-12-23
BR112017019140A2 (pt) 2018-05-02
JP6856534B2 (ja) 2021-04-07
US20220211829A1 (en) 2022-07-07
RU2729362C2 (ru) 2020-08-06
WO2016146035A1 (en) 2016-09-22
RU2017134270A (ru) 2019-04-04
US20210113676A1 (en) 2021-04-22
CN115607659A (zh) 2023-01-17
HK1249130A1 (zh) 2018-10-26
JP2018512380A (ja) 2018-05-17
WO2016145578A1 (en) 2016-09-22
EP3268465A1 (en) 2018-01-17
US10967054B2 (en) 2021-04-06
JP7244117B2 (ja) 2023-03-22
JP2022111272A (ja) 2022-07-29
CA2975602A1 (en) 2016-09-22
US12312597B2 (en) 2025-05-27

Similar Documents

Publication Publication Date Title
IL253795B (en) Methods for treating cancer using activated t cells
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
IL250677A0 (en) Cancer treatment using anti-nkg2a agents
GB201701673D0 (en) Methods of well treatment
PL3851537T3 (pl) Leczenie hiperbilirubinemii
SMT202100115T1 (it) Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
SG11201607130RA (en) Combination method for treatment of cancer
EP3193905A4 (en) Methods of treating cervical cancer
IL247859A0 (en) Cancer treatment
IL246607A0 (en) Improved cellular preparations and methods for cancer treatment
EP3119390A4 (en) Methods of treating cancer
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201409363D0 (en) Skin cancer treatment
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
GB201522433D0 (en) Cancer treatment
GB201407837D0 (en) Methods of cancer therapy
GB201417456D0 (en) Treatment of cancer
GB201512139D0 (en) Methods of treatment
EP3125878A4 (en) Methods of treating breast cancer
GB201409362D0 (en) Treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted